Clinical Trials

A Multicentre, phase 3, randomized, double-blind, placebo-controlled study with an active-reference drug evaluating the efficacy and safety of bimekizumab in the treatment of subjects with active psoriatic arthritis
A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease Modifying Therapies

A Phase 4 open-label randomized controlled study Comparing the effectiveness of adalimumab Introduction and methotrexate dose escalation in subjects with Psoriatic Arthritis (CONTROL)
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (RESOLVE-1)
A Multi-Centre Double-Blind Randomised Placebo-Controlled Trial of Oral Anticoagulation with Apixaban in Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SPHInX)
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS) Prospective observational cohort of patients with moderate-to-severe SLE to characterize cross-sectional and longitudinal disease activity, treatment patterns and effectiveness, outcomes and comorbidities, healthcare resource utilization, and the impact of SLE on quality of life by type I interferon gene expression (SPOCs)

CNTO1959PSA3001: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis including those Previously Treated with Biologic Anti-TNF? Agent(s) (DISCOVER-1)
An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SENSCIS-ON)

2016-2019: A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SENSCIS)
2016-2019: Long-Term Experience with Abatacept SC in Routine Clinical Practice Study (ASCORE)
2015-2018: A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
2015-2017: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus

For more information on any of the trials, please visit